Mount Sinai Health System · 15 hours ago
Postdoctoral Fellow-MSH-30025-237
Maximize your interview chances
Health CareHospital
Actively Hiring
Insider Connection @Mount Sinai Health System
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
The research study focuses on functional genomics and mouse models to understand the consequences of genetic and epigenetic alterations in lung cancer.
You will participate in research to achieve a systematic and comprehensive understanding of the mechanisms of DNA repair, DNA damage responses, phenotypic plasticity, immune regulatory pathways, and immune escape mechanisms in human malignancies with a primary focus on lung cancer.
You will employ in vitro and in vivo models of lung cancer, multiple high-throughput screening technologies, genomics, proteomics, CRISPR engineering, and clinical samples to assess DNA repair, DNA damage responses, and immune sensing pathways, and evaluate their effects on therapeutic response.
You will apply advanced molecular assays including CRISPR screening, immunological analysis, pharmacological evaluations, single-cell RNAseq, and/or spatial transcriptomics to provide critical insights into the molecular circuitry that drives lung cancers and, consequently, results in the development of novel therapeutic strategies for the clinically relevant molecular subsets of lung cancer.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
PhD
Experience Required: yes
Company
Mount Sinai Health System
Mount Sinai Health System delivers integrated medical care, research, and medical education through its network.
Funding
Current Stage
Late StageTotal Funding
$34.9MKey Investors
Hearst Health Prize.Multiple Myeloma Research FoundationSteven & Alexandra Cohen Foundation
2024-06-06Grant· $0.1M
2023-11-02Grant· $7M
2023-09-20Grant· $6.2M
Leadership Team
Recent News
2024-11-04
2024-11-02
2024-06-04
Company data provided by crunchbase